SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Chiroscience -- Ignore unavailable to you. Want to Upgrade?

To: UPAL who wrote (49)2/16/1999 4:30:00 PM
From: nigel bates  Respond to of 69
 
It's probably already in the price. Be interesting to see who picks up Chirocaine when it gets 'dumped'.

nig



To: UPAL who wrote (49)2/16/1999 10:36:00 PM
From: A.J. Mullen  Read Replies (1) | Respond to of 69
 
James Capel, a big British broker, has a hold recommendation for Chiroscience. They specifically note that a collapse of the Astra_Zeneca merger would be positive for CRO. That's unlikely to happen but it would be very good if either the European or US regulators insist that they divest themselves of their interest in Chirocaine. I suspect Chiroscience could get a better deal now.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News